MXPA06001588A - Reactivos de peptido especificos de prion. - Google Patents

Reactivos de peptido especificos de prion.

Info

Publication number
MXPA06001588A
MXPA06001588A MXPA06001588A MXPA06001588A MXPA06001588A MX PA06001588 A MXPA06001588 A MX PA06001588A MX PA06001588 A MXPA06001588 A MX PA06001588A MX PA06001588 A MXPA06001588 A MX PA06001588A MX PA06001588 A MXPA06001588 A MX PA06001588A
Authority
MX
Mexico
Prior art keywords
peptide
prion
pathogenic
sample
peptide reagent
Prior art date
Application number
MXPA06001588A
Other languages
English (en)
Spanish (es)
Inventor
Michael D Connolly
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of MXPA06001588A publication Critical patent/MXPA06001588A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2828Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
MXPA06001588A 2003-08-13 2004-08-13 Reactivos de peptido especificos de prion. MXPA06001588A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49496203P 2003-08-13 2003-08-13
US57036804P 2004-05-12 2004-05-12
US58650904P 2004-07-09 2004-07-09
PCT/US2004/026363 WO2005016127A2 (en) 2003-08-13 2004-08-13 Prion-specific peptide reagents

Publications (1)

Publication Number Publication Date
MXPA06001588A true MXPA06001588A (es) 2006-08-25

Family

ID=34198970

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06001588A MXPA06001588A (es) 2003-08-13 2004-08-13 Reactivos de peptido especificos de prion.

Country Status (13)

Country Link
US (1) US7439041B2 (OSRAM)
EP (1) EP1653844B1 (OSRAM)
JP (3) JP4709149B2 (OSRAM)
KR (1) KR101166012B1 (OSRAM)
AU (2) AU2004264953B2 (OSRAM)
BR (1) BRPI0413495A (OSRAM)
CA (1) CA2535261C (OSRAM)
DK (1) DK1653844T3 (OSRAM)
ES (1) ES2398394T3 (OSRAM)
IL (1) IL173480A0 (OSRAM)
MX (1) MXPA06001588A (OSRAM)
NZ (2) NZ545385A (OSRAM)
WO (1) WO2005016127A2 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011000A (es) 2001-05-31 2004-02-27 Arete Associates Metodo de sensor de proteinas deformadas.
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
NZ545385A (en) * 2003-08-13 2010-12-24 Novartis Vaccines & Diagnostic Prion-specific peptide reagents
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
WO2006076497A2 (en) 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
CA2594840A1 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Elisa assays using prion-specific peptide reagents
CA2597912C (en) * 2005-02-15 2013-06-04 Adlyfe, Inc. Method for detecting misfolded proteins and prions
WO2006128690A1 (en) * 2005-06-01 2006-12-07 Micromet Ag Anti-il2 antibodies
CN101356186A (zh) 2005-09-09 2009-01-28 诺华有限公司 朊病毒-特异性拟肽试剂
GB0519198D0 (en) * 2005-09-20 2005-10-26 Univ Cambridge Tech Tse detection
MX2009001079A (es) * 2006-07-28 2009-02-10 Adlyfe Inc Sondas de peptido para diagnosis y terapeutica.
US20100291598A1 (en) * 2007-04-04 2010-11-18 David Peretz Prion elisa
JP2010523977A (ja) * 2007-04-04 2010-07-15 ノバルティス アーゲー プリオンアッセイ
WO2009041902A1 (en) * 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
US8709472B1 (en) * 2007-11-13 2014-04-29 Abbott Cardiovascular Systems Inc. Bioactive agent-loaded heart-targeting nanoparticles
CN102083450A (zh) * 2008-04-30 2011-06-01 诺华有限公司 致病性构象异构体的分析
EP2128618A1 (en) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. A process for monitoring the presence of pathogenic agents in biological fluids by nanostructured materials
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
US9125846B2 (en) 2010-10-15 2015-09-08 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
AU2016338410B2 (en) 2015-10-14 2021-07-15 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
AU2017263706B2 (en) * 2016-05-10 2020-04-09 Lg Electronics Inc. Mobile robot and control method therefor
WO2018005330A1 (en) * 2016-06-27 2018-01-04 Florida State University Research Foundation, Inc. Modified fragments from the octarepeat region of prion protein as hemin binders
US11660325B2 (en) 2016-09-19 2023-05-30 University Of Houston System Compositions and methods of targeting cancer stem cells
JP2021004175A (ja) * 2017-09-04 2021-01-14 国立大学法人東北大学 コンフォメーション病治療用材料、及びその製造方法、並びにコンフォメーション病医薬のスクリーニング方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773572A (en) 1991-12-03 1998-06-30 Proteus Molecular Design Limited Fragments of prion proteins
WO1993023432A1 (en) 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
EP1416280A3 (en) * 1995-09-14 2005-08-10 The Regents of the University of California Antibodies specific for native PrPsc
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
WO1998035236A2 (en) 1997-02-06 1998-08-13 Enfer Technology Limited Immunological assay for spongiform encephalopathies
EP0861900A1 (en) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
WO1999053036A2 (en) * 1998-04-14 1999-10-21 Sugen, Inc. Ste20-related protein kinases
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
FI982480A0 (fi) 1998-11-17 1998-11-17 Wallac Oy Immunomääritys nisäkkäiden tarttuvan spongiomuotoisen aivotaudin määrittämiseksi
EP1169646A2 (en) 1999-01-25 2002-01-09 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
JP2003521477A (ja) 1999-06-23 2003-07-15 カプリオン ファーマシューティカルズ インコーポレーティッド プリオン蛋白質ペプチドおよびその使用
CA2379237A1 (en) 1999-07-27 2001-02-01 Imperial College Innovations Limited Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
JP2003514773A (ja) * 1999-09-28 2003-04-22 ウニヴェルジテート チューリッヒ 血清及び血漿中のプリオン結合活性を有する因子並びに伝染性海綿状脳障害を検出するための薬剤
FR2801106B1 (fr) 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
EP1272509A2 (en) 2000-04-05 2003-01-08 V.I. Technologies, Inc. Prion-binding peptidic ligands and methods of using same
AU2001255735A1 (en) * 2000-04-28 2001-11-12 Synuthane International, Inc. Double metal cyanide catalysts containing polyglycol ether complexing agents
WO2001097785A2 (en) 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
SI1299729T1 (sl) 2000-07-07 2006-10-31 Applied Research Systems Zgodnja diagnoza konformacijskega obolenja
GB0103508D0 (en) * 2001-02-13 2001-03-28 Univ Dundee Screening method and agents
MXPA03011000A (es) 2001-05-31 2004-02-27 Arete Associates Metodo de sensor de proteinas deformadas.
CA2466841A1 (en) 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
WO2003050139A2 (en) 2001-12-10 2003-06-19 Applied Research Systems Ars Holding N.V. Prion inhibiting peptides and derivatives thereof
US7659076B2 (en) 2002-02-28 2010-02-09 Microsens Biophage Limited Binding of pathological forms of prion proteins
EP1572937B1 (en) 2002-04-09 2012-02-08 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
US20040208919A1 (en) 2002-06-13 2004-10-21 Nicolau Yves C. Vaccination against prion diseases
DE10230141B4 (de) 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
EP1382971A1 (en) * 2002-07-17 2004-01-21 Pepscan Systems B.V. Detection of prion disease
EP1534746A2 (en) 2002-08-23 2005-06-01 Copenhagen Biotech Assets APS Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
AU2002342850A1 (en) 2002-10-23 2004-05-13 Centre For Research And Technology Hellas/Institute Of Agrobiotechnology In.A Prion protein-binding peptide sequences
AU2002352042A1 (en) 2002-11-18 2004-06-15 Prionics Ag Method for the detection of prpsc
MXPA05005920A (es) 2002-12-03 2006-03-17 American Nat Red Cross Ligandos de proteina prion y metodos de uso.
EP1457500A1 (en) 2003-03-14 2004-09-15 University of Zurich Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalophathies
PL1615992T3 (pl) 2003-04-04 2014-03-31 Pathogen Removal And Diagnostic Tech Inc Materiały wiążące białko prionowe i sposoby ich zastosowania
EP1616036A4 (en) 2003-04-14 2007-03-21 Pathogen Removal And Diagnosti PROCESS FOR IDENTIFYING LIGANDS SPECIFIC TO STRUCTURAL FORMS OF PROTEINS
NZ545385A (en) * 2003-08-13 2010-12-24 Novartis Vaccines & Diagnostic Prion-specific peptide reagents
DE102004043782A1 (de) 2004-09-08 2006-03-09 Heinrich-Heine-Universität Düsseldorf Polypeptide und Verfahren zur spezifischen Bindung von Prionen
US20060057671A1 (en) 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins

Also Published As

Publication number Publication date
NZ545385A (en) 2010-12-24
CA2535261C (en) 2015-11-24
JP2013033060A (ja) 2013-02-14
IL173480A0 (en) 2006-06-11
EP1653844A2 (en) 2006-05-10
AU2009225337A1 (en) 2009-11-05
JP2007502120A (ja) 2007-02-08
AU2004264953B2 (en) 2009-07-23
EP1653844B1 (en) 2012-12-12
AU2009225337B2 (en) 2012-12-06
ES2398394T3 (es) 2013-03-15
EP1653844A4 (en) 2009-01-14
DK1653844T3 (da) 2013-03-11
BRPI0413495A (pt) 2006-10-17
NZ580256A (en) 2011-07-29
HK1090275A1 (en) 2006-12-22
WO2005016127A2 (en) 2005-02-24
JP4709149B2 (ja) 2011-06-22
US20050118645A1 (en) 2005-06-02
KR20060066088A (ko) 2006-06-15
US7439041B2 (en) 2008-10-21
AU2004264953A1 (en) 2005-02-24
WO2005016127A3 (en) 2006-12-21
JP2010158247A (ja) 2010-07-22
KR101166012B1 (ko) 2012-07-23
CA2535261A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
AU2009225337B2 (en) Prion-specific peptide reagents
US20090061462A1 (en) Prion-specific peptide reagents
JP2012181210A (ja) プリオン特異的ペプチド試薬を使用するelisaアッセイ
JP2008527382A5 (OSRAM)
US20090191571A1 (en) Isolation and Detection of Pathogenic Prions
RU2381033C2 (ru) Специфичные в отношении прионов пептидные реагенты
CN1984669B (zh) 朊病毒特异性的肽试剂
HK1090275B (en) Prion-specific peptide reagents

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration